Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$0.27 - $11.9 $12,619 - $556,206
-46,740 Reduced 43.31%
61,175 $18,000
Q3 2022

Oct 13, 2022

BUY
$0.51 - $10.4 $3,991 - $81,390
7,826 Added 7.82%
107,915 $0
Q4 2021

Feb 02, 2022

BUY
$1.14 - $1.58 $54,833 - $75,998
48,100 Added 92.52%
100,089 $114,000
Q3 2021

Nov 10, 2021

SELL
$1.39 - $2.1 $191,301 - $289,016
-137,627 Reduced 72.58%
51,989 $79,000
Q2 2021

Aug 17, 2021

BUY
$1.56 - $2.26 $273,742 - $396,575
175,476 Added 1240.99%
189,616 $375,000
Q1 2021

May 14, 2021

BUY
$1.77 - $2.98 $25,027 - $42,137
14,140 New
14,140 $26,000

About Hepion Pharmaceuticals, Inc.


  • Ticker HEPA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,229,600
  • Market Cap $35.1M
  • Description
  • Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver...
More about HEPA
Track This Portfolio

Track Pvg Asset Management Corp Portfolio

Follow Pvg Asset Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pvg Asset Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Pvg Asset Management Corp with notifications on news.